Clinical Trial Update: OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone [Phase 2]

View source ↗

Summary

Phase 2 trial update for OGX-427 in metastatic castration-resistant prostate cancer with PSA progression on abiraterone; study status terminated with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• OGX-427 (apatorsen)

Snippet

Sponsor: Costantine Albany | Conditions: Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-10-18